As of 2025-09-18, the Intrinsic Value of Inozyme Pharma Inc (INZY) is -8.26 USD. This INZY valuation is based on the model Peter Lynch Fair Value. With the current market price of 4.00 USD, the upside of Inozyme Pharma Inc is -306.62%.
Based on its market price of 4.00 USD and our intrinsic valuation, Inozyme Pharma Inc (INZY) is overvalued by 306.62%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -8.26 - -8.26 | -8.26 | -306.62% |
| P/E | (11.31) - (19.08) | (14.42) | -460.6% |
| DDM - Stable | (11.33) - (33.25) | (22.29) | -657.2% |
| DDM - Multi | (9.27) - (21.91) | (13.11) | -427.8% |
| Market Cap (mil) | 258.24 |
| Beta | 5.56 |
| Outstanding shares (mil) | 64.56 |
| Enterprise Value (mil) | 278.68 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.34% |
| Cost of Debt | 5.00% |
| WACC | 10.18% |